Carvana shares are trading higher Wednesday as investors piled into small caps on growing conviction that the Federal Reserve will cut interest rates at next week's policy meeting.
Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, with enrollment ongoing into 2026.